← Back to Search

Monoclonal Antibodies

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis (FRONTIER 2 Trial)

Phase 2

Waitlist Available

Research Sponsored by Janssen Research & Development, LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to week 40

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new drug called JNJ-77242113 for people with moderate-to-severe plaque psoriasis. These patients often need better treatments. The drug aims to improve their skin by changing how their immune system works.

Eligible Conditions

Plaque Psoriasis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to week 40

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to week 40

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 40 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 36

Secondary study objectives

Change From Baseline in PASI Total Score at Week 36

Change from Baseline in PSSD Signs Score at Week 36

Change from Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 36

+7 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups

Experimental Treatment

Group I: Group 6: JNJ-77242113 Dose 3 QDExperimental Treatment1 Intervention

Participants originally randomized to placebo in originating Study 77242113PSO2001 will receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.

Group II: Group 5: JNJ-77242113 Dose 3 BIDExperimental Treatment1 Intervention

Participants originally randomized to JNJ-77242113 Dose 3 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 BID from Week 0 through Week 36 in this study.

Group III: Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)Experimental Treatment1 Intervention

Participants originally randomized to JNJ-77242113 Dose 1 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 BID from Week 0 through Week 36 in this study.

Group IV: Group 3: JNJ-77242113 Dose 3 QDExperimental Treatment1 Intervention

Participants originally randomized to JNJ-77242113 Dose 3 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.

Group V: Group 2: JNJ-77242113 Dose 2 QDExperimental Treatment1 Intervention

Participants originally randomized to JNJ-77242113 Dose 2 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 2 QD from Week 0 through Week 36 in this study.

Group VI: Group 1: JNJ-77242113 Dose 1 Once Daily (QD)Experimental Treatment1 Intervention

Participants originally randomized to JNJ-77242113 Dose 1 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 QD from Week 0 through Week 36 in this study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

JNJ-77242113

2022

Completed Phase 2

~640

Do I qualify?Apply below to find out